Criticism of Kennedy’s Vaccine Policy
James Carville, known for his vibrant personality in the Democratic Party, recently remarked that Bobby Kennedy’s vaccine policies might cause more harm than any cabinet secretary in history, calling them “idiotic.”
His main point of contention? Kennedy, the Secretary of Health and Human Services, recently dismissed every Biden administration appointee from the Advisory Committee on Immunization Practices (ACIP). He replaced them with a new group of respected medical professionals and scientists from prestigious institutions like Harvard and MIT, who bring expertise in fields like virology and infectious diseases.
The Pharmaceutical Research and Manufacturers of America (PhRMA), while not as dramatic as Carville, voiced their concerns. The American Medical Association stated that Kennedy’s actions could damage public trust in vaccines. Senator Bernie Sanders labeled the firings as “reckless” and advocated for a bipartisan investigation into the matter.
It seems there’s a coalition of corporate leaders and left-leaning politicians united against Kennedy’s shifts.
A Shift in Politics
Election outcomes have tangible impacts on both personnel and policies—it’s a fundamental aspect of functioning democracies.
Kennedy’s new team is focused on re-evaluating the safety and efficacy of COVID-19 vaccines, which is something the previous administration notably neglected. There was clear evidence suggesting that these vaccines did not prevent infections yet mandates were enforced regardless. The previous administration’s commitment to “evidence-based” medicine often fell short.
Moreover, the Biden team didn’t adequately warn the public about significant risks, such as myocarditis in younger populations, a concern highlighted in recent Senate reports.
In many ways, it could be argued that the Biden administration inadvertently fueled “vaccine skepticism.”
Meanwhile, Kennedy’s skeptics might benefit from taking a moment to compose themselves.
The newly appointed ACIP members recently wrapped up their initial meetings, during which they engaged with the CDC and others and discussed pressing vaccine topics, including the vaccination guidelines for infants against respiratory syncytial virus (RSV), which can be quite severe.
A New Approach
One notable recommendation from the panel was to expand RSV vaccine options for children and infants. Currently, pregnant mothers receive the Abysvo vaccine, while infants are given Nirsevimab. The panel has now also considered introducing Clesrovimab, a long-lasting monoclonal antibody as an alternative for infants.
The committee voted 5 to 2 in favor of adding Clesrovimab to its recommendations. PhRMA expressed their support for this decision.
One of the more contentious discussions involved thimerosal, a vaccine preservative that contains ethylmercury—distinct from the more toxic methylmercury. Thimerosal has been at the heart of heated debates regarding its connection to autism and other disorders. In 1999, health authorities recommended its swift removal from childhood vaccines out of caution.
During their first meeting, the ACIP specifically tackled whether thimerosal should remain a preservative in seasonal flu vaccines and the use of single versus multidose vials.
The panel voted 5 to 1, with one abstention, to endorse seasonal flu vaccinations for all adults using a single-dose formulation without thimerosal—a notable shift from earlier practices.
Room for Discussion
Kennedy’s critics should recognize that the new ACIP isn’t simply a rubber stamp for decisions.
For instance, Dr. H. Cody Meissner, a former member, voiced strong disagreement regarding the thimerosal decision, advocating for a focus on scientific evidence, which he claims does not indicate harm from thimerosal. He argued that the flu’s known risks outweigh the “nonexistent” risks from the preservative.
Dr. Retsef Levi from MIT expressed his dissent on the RSV vaccination changes, emphasizing the need for more comprehensive investigations into vaccination effects and advocating for a parent-focused perspective on recommendations.
PhRMA remains cautious regarding the ACIP’s discussions on thimerosal and childhood vaccination schedules.
The ACIP primarily serves an advisory role, offering guidance to the CDC regarding vaccine schedules. Dr. Susan Monarez, Donald Trump’s nominee for CDC director, affirmed her commitment to vaccine access, noting their role in reducing childhood mortality.
In response to queries about mRNA vaccine safety, Monarez pointed to a prior FDA assessment, although the new FDA Commissioner, Dr. Marty Makary, indicated a commitment to reassessing that evaluation. Meanwhile, the CDC has now acknowledged myocarditis as a notable adverse effect linked to COVID-19 vaccinations in young adults, especially young men, and this information will be shared with the public moving forward.
Looking Ahead
Documented adverse events tied to COVID-19 vaccinations have been corroborated in recent Senate testimonies. Given the existing data regarding certain negative effects, it would be prudent for the FDA to consider issuing a “black box” warning, which indicates potential risks associated with approved drugs. It’s also reasonable for the FDA to approve a commercially available test for assessing levels of the coronavirus spike protein from vaccinations.
Kennedy’s newly appointed team of medical experts appear well-qualified, thoughtful, and committed to public health. Perhaps it’s time for his critics to take a step back.
